Akston Biosciences, a United States-based company that deals with insulin engineering, has collaborated with LakePharma, a United States-based CRDMO serving the biotechnology community, to produce commercial quantities of Akston's adjuvated COVID-19 vaccine candidate, AKS-452, it was reported on Tuesday.
The vaccine candidate is scheduled to commence phase 1/2 clinical testing later this month.
AKS-452 is a COVID-19-specific Fc fusion protein vaccine that is in commercial development and is designed to induce or boost a Th1/Th2 mixed immune response in patients against the Receptor Binding Domain of the novel SARS-CoV-2 coronavirus spike protein. It is shelf-stable for weeks at up to 37 degrees Celsius and is engineered to use conventional antibody manufacturing techniques.
Dorton, Davis Added to Sonoma Biotherapeutics B of Directors
Atomwise Signs Multi-Target Research Collaboration with Sanofi
WuXi STA announces ground-breaking for new in Delaware pharmaceutical manufacturing campus
Pneumagen doses first participant in Neumifil phase two controlled human infection challenge study
South Rampart Pharma names new chief financial officer
BeiGene Forms Strategic Alliance with Ontada to Improve US Community Oncology Care